Taberminogene vadenovec

N/A

Report date: 2023/10/26 16:14:46

Base Information

Drug NameTaberminogene vadenovec
Drug Alias NameEG004Vascular endothelial growth factor D gene therapy (Ark Therapeutics)Trinam
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionVascular endothelial growth factor D stimulantsGene transference
TargetsVascular endothelial growth factor D
Therapy Area/IndicationsVascular restenosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArk Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArk Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsVascular restenosis

Other Information

ATC CodeN/A
Related LinksN/A